Also known as: Anti-Obesity Drug 9604 · hGH Fragment 177-191 · Tyr-hGH Frag 177-191
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue. Unlike full HGH, it stimulates lipolysis and inhibits lipogenesis without affecting growth, IGF-1 levels, insulin sensitivity, or blood glucose — making it a targeted fat-loss agent. FDA GRAS status granted in 2014.
AOD-9604 was developed at Monash University, Australia, by researchers who identified that the lipolytic properties of growth hormone resided in its C-terminal region (residues 177–191). This selective profile is its key differentiator from HGH: it does not elevate IGF-1, it does not affect insulin signaling, and the FDA has granted it GRAS (Generally Recognized as Safe) status as a food ingredient in 2014.
AOD-9604 stimulates lipolysis in adipocytes through a beta-3 adrenergic receptor-like mechanism — independent of the IGF-1 pathway used by full HGH. It activates hormone-sensitive lipase, triggering triglyceride hydrolysis.
Inhibits fatty acid synthase (FAS) expression in adipose tissue, reducing de novo lipogenesis. This dual action creates a net negative fat balance.
Independently stimulates proteoglycan synthesis in cartilage and has been investigated for osteoarthritis treatment via intra-articular injection.
AOD-9604 is one of the safest metabolic peptides due to its highly selective mechanism — it does not affect IGF-1, blood glucose, insulin sensitivity, or growth. It is not anabolic and produces no hormonal side effects. FDA GRAS status confirms its favorable safety profile. It is most effective when paired with fasted cardio, caloric deficit, and adequate protein intake. Not effective as a standalone obesity treatment at clinical scale — best used as part of a comprehensive body composition protocol.
AOD-9604 does not suppress natural GH production or IGF-1, so there is no mandatory cycling requirement based on receptor downregulation. However, cycling is used in research protocols to assess effects, prevent any potential receptor adaptation, and allow evaluation of maintained results during off-phase. Effects persist modestly beyond the treatment period due to changes in adipocyte enzyme expression.
Phase 2b/3 clinical trials in Australia showed dose-dependent fat mass reduction without changes in lean mass, IGF-1, or glucose metabolism. FDA GRAS status granted 2014. Cartilage repair Phase 2 showed significant WOMAC improvements in knee OA patients.
Ask anything about AOD-9604 — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial ge…